TWI720032B - N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法 - Google Patents

N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法 Download PDF

Info

Publication number
TWI720032B
TWI720032B TW105132676A TW105132676A TWI720032B TW I720032 B TWI720032 B TW I720032B TW 105132676 A TW105132676 A TW 105132676A TW 105132676 A TW105132676 A TW 105132676A TW I720032 B TWI720032 B TW I720032B
Authority
TW
Taiwan
Prior art keywords
pyrazolo
pyridine
phenyl
cyclobutyl
formamide
Prior art date
Application number
TW105132676A
Other languages
English (en)
Chinese (zh)
Other versions
TW201722948A (zh
Inventor
哈里德 艾卡里
路克 喬納森 艾爾維
薩維爾 馬里 布克
布萊恩 S 布朗
皮爾特 伊莎貝爾 羅傑 克拉斯
馬爾龍 D 寇瓦特
艾莎 列莫斯
尼可拉斯 德斯羅伊
貝倫傑 杜席昂
葛雷高里 A 葛非瑟
羅曼 露克 馬里 高斯米尼
克里斯多夫 蓋坦 豪斯曼
柯恩 卡瑞爾 詹森
建國 紀
菲利浦 R 肯
琴-米奇爾 樂法蘭柯斯
奧斯卡 曼默爾堤
克里斯提爾 琴尼 馬里 曼奈特
努莉雅 梅拉悠 梅拉悠
葛雷高里 約翰 羅伯特 紐桑姆
阿戴林 馬里 艾里斯 帕里斯
薩金 V 帕泰爾
馬修 拉法爾 皮桑羅
艾努魯帕 薛斯薩
伊利沙貝斯 C 史維福特
德 普拉斯 史蒂芬 艾蜜勒 凡
王學慶
貝力克 安 廸
Original Assignee
比利時商葛萊伯格有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商葛萊伯格有限公司 filed Critical 比利時商葛萊伯格有限公司
Publication of TW201722948A publication Critical patent/TW201722948A/zh
Application granted granted Critical
Publication of TWI720032B publication Critical patent/TWI720032B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW105132676A 2015-10-09 2016-10-07 N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法 TWI720032B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562239647P 2015-10-09 2015-10-09
US62/239,647 2015-10-09
US201662309794P 2016-03-17 2016-03-17
US62/309,794 2016-03-17

Publications (2)

Publication Number Publication Date
TW201722948A TW201722948A (zh) 2017-07-01
TWI720032B true TWI720032B (zh) 2021-03-01

Family

ID=57209654

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105132676A TWI720032B (zh) 2015-10-09 2016-10-07 N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法

Country Status (32)

Country Link
US (4) US9890158B2 (enExample)
EP (1) EP3359541B1 (enExample)
JP (1) JP6779992B2 (enExample)
KR (1) KR20180083323A (enExample)
CN (1) CN108513574B (enExample)
AU (1) AU2016333856C1 (enExample)
BR (1) BR112018007161B1 (enExample)
CA (1) CA3001096A1 (enExample)
CL (1) CL2018000911A1 (enExample)
CO (1) CO2018003716A2 (enExample)
CR (1) CR20180215A (enExample)
CY (1) CY1123545T1 (enExample)
DK (1) DK3359541T3 (enExample)
EC (1) ECSP18032223A (enExample)
ES (1) ES2829636T3 (enExample)
HR (1) HRP20201618T1 (enExample)
HU (1) HUE051067T2 (enExample)
IL (1) IL258553A (enExample)
LT (1) LT3359541T (enExample)
MX (1) MX379276B (enExample)
NZ (1) NZ741223A (enExample)
PE (1) PE20181348A1 (enExample)
PH (1) PH12018500765B1 (enExample)
PL (1) PL3359541T3 (enExample)
PT (1) PT3359541T (enExample)
RU (1) RU2724345C2 (enExample)
SG (1) SG11201802932VA (enExample)
SI (1) SI3359541T1 (enExample)
TW (1) TWI720032B (enExample)
UY (1) UY36943A (enExample)
WO (1) WO2017060874A1 (enExample)
ZA (1) ZA201802976B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3183254T1 (sl) 2014-08-21 2019-08-30 Boehringer Ingelheim International Gmbh Nove spiro(3H-indol-3,2'pirolidin)-2(1H)-onske spojine in derivati kot inhibitorji MDM2-P53
AR106314A1 (es) 2015-10-09 2018-01-03 Boehringer Ingelheim Int COMPUESTOS DE ESPIRO[3H-INDOL-3,2’-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53
WO2017060874A1 (en) 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
EP3983388A1 (en) * 2019-06-12 2022-04-20 Nodthera Limited Sulfonamide derivatives and uses thereof
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
US12410208B2 (en) * 2019-08-09 2025-09-09 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-D-galactopyranoside derivatives
WO2021116055A1 (en) 2019-12-10 2021-06-17 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
PT4146348T (pt) 2020-05-08 2024-10-04 Halia Therapeutics Inc Inibidores da quinase nek7
WO2021252488A1 (en) 2020-06-08 2021-12-16 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
KR20240155228A (ko) 2022-02-03 2024-10-28 버텍스 파마슈티칼스 인코포레이티드 (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
CN118974059A (zh) 2022-02-08 2024-11-15 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
CN119947720A (zh) 2022-05-16 2025-05-06 弗特克斯药品有限公司 治疗囊性纤维化的方法
CN115806532A (zh) * 2022-08-31 2023-03-17 大连百傲化学股份有限公司 一种mit中杂质的制备方法
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
CN115960100B (zh) * 2022-12-28 2023-08-18 北京康立生医药技术开发有限公司 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081820A1 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
EP1735314A1 (en) * 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
NZ587549A (en) 2004-06-24 2012-10-26 Vertex Pharma 6-Amino-indole derivatives and processes for their preparation
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
MXPA06014699A (es) * 2004-07-05 2007-03-26 Astellas Pharma Inc Derivados de pirazolo-piridina.
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
JP5686596B2 (ja) 2007-05-25 2015-03-18 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
AU2009308241B2 (en) 2008-10-23 2016-01-07 Vertex Pharmaceuticals Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl) phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
HUE026271T2 (en) * 2010-09-14 2016-05-30 Inst Biochemii I Biofizyki Pan Mutant CFTR protein modulator compounds and their use for the treatment of diseases that interfere with CFTR protein function disorders
RU2599144C2 (ru) 2010-10-08 2016-10-10 Нивалис Терапьютикс,Инк. Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
US9630929B2 (en) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2994463B1 (en) 2013-05-07 2017-10-25 Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
WO2015018823A1 (en) 2013-08-08 2015-02-12 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
MX2016010056A (es) * 2014-02-06 2016-11-15 Abbvie Inc 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
MY194313A (en) 2014-10-31 2022-11-27 Galapagos Nv Substituted chromanes and method of use
MX2017005663A (es) 2014-10-31 2018-03-01 Abbvie Sarl Tetrahidropiranos sustituidos y metodo de uso.
WO2017060874A1 (en) * 2015-10-09 2017-04-13 Abbvie S.Á.R.L N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10130622B2 (en) * 2015-10-09 2018-11-20 Abbvie S.Á.R.L. Compounds for treatment of cystic fibrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081820A1 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors

Also Published As

Publication number Publication date
ZA201802976B (en) 2019-07-31
JP2018529743A (ja) 2018-10-11
ECSP18032223A (es) 2018-05-31
RU2018115722A (ru) 2019-11-12
EP3359541A1 (en) 2018-08-15
SI3359541T1 (sl) 2021-01-29
BR112018007161A2 (pt) 2018-10-30
US10259810B2 (en) 2019-04-16
SG11201802932VA (en) 2018-05-30
KR20180083323A (ko) 2018-07-20
US20180105522A1 (en) 2018-04-19
JP6779992B2 (ja) 2020-11-04
WO2017060874A1 (en) 2017-04-13
AU2016333856C1 (en) 2021-12-09
IL258553A (en) 2018-05-31
MX379276B (es) 2025-03-10
UY36943A (es) 2017-05-31
US10647717B2 (en) 2020-05-12
ES2829636T3 (es) 2021-06-01
LT3359541T (lt) 2020-11-25
US20190202823A1 (en) 2019-07-04
HUE051067T2 (hu) 2021-01-28
RU2724345C2 (ru) 2020-06-23
PH12018500765A1 (en) 2018-10-01
CL2018000911A1 (es) 2018-08-24
PL3359541T3 (pl) 2021-01-11
BR112018007161B1 (pt) 2024-01-16
AU2016333856B2 (en) 2021-05-20
CO2018003716A2 (es) 2018-07-19
EP3359541B1 (en) 2020-08-05
CN108513574A (zh) 2018-09-07
HRP20201618T1 (hr) 2020-12-25
NZ741223A (en) 2023-03-31
US20170101405A1 (en) 2017-04-13
CR20180215A (es) 2018-06-05
MX2018004359A (es) 2018-05-01
AU2016333856A1 (en) 2018-04-26
US9890158B2 (en) 2018-02-13
US20190330207A1 (en) 2019-10-31
RU2018115722A3 (enExample) 2020-02-18
CA3001096A1 (en) 2017-04-13
PE20181348A1 (es) 2018-08-22
PT3359541T (pt) 2020-11-11
TW201722948A (zh) 2017-07-01
CY1123545T1 (el) 2022-03-24
DK3359541T3 (da) 2020-11-09
PH12018500765B1 (en) 2020-11-25
CN108513574B (zh) 2021-01-05

Similar Documents

Publication Publication Date Title
TWI720032B (zh) N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法
US12077536B2 (en) BCL-2 inhibitors
EP3145929B1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
JP2018530557A (ja) 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用
BR112020019264A2 (pt) Compostos para tratar doença de huntington
EA019785B1 (ru) Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение
KR20190040319A (ko) N-(피리딘-2-일)피리딘-술폰아미드 유도체 및 질환의 치료에서 이들의 용도
EP4506349A2 (en) Tetrahydrothieno pyridine derivatives as ddrs inhibitors
EA046152B1 (ru) Соединения для лечения болезни гентингтона
HK1245783A1 (en) Triazolopyridine compounds and methods of use thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees